表紙
市場調査レポート

ジェネリック医薬品の世界市場予測 (2016〜2026年)

Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets

発行 Visiongain Ltd 商品コード 220569
出版日 ページ情報 英文 306 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.49円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ジェネリック医薬品の世界市場予測 (2016〜2026年) Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets
出版日: 2016年04月18日 ページ情報: 英文 306 Pages
概要

ジェネリック医薬品市場は2016年に2,546億米ドルの規模に達する見込みです。調査期間中、高齢者人口の増加、医療費節約戦略、そして新興経済国の急成長などにより高い収益成長が見込まれます。

当レポートでは、世界のジェネリック医薬品市場について調査し、市場の今後の見通しと地域別動向、2026年までの収益予測、大手企業のプロファイルなどをまとめています。

第1章 レポートの概要

第2章 ジェネリック医薬品のイントロダクション

  • ジェネリック医薬品の隆盛
  • ジェネリック医薬品とは
  • 医薬品業業界の概要
  • 生物学的同等性の実証
  • ジェネリック医薬品の種類
  • 合成ジェネリック医薬品
  • ジェネリック医薬品市場の分類
  • ジェネリックの代用は大規模な医薬品ビジネスにとって悪い知らせか?
  • ジェネリック医薬品に対する法規制
  • 強制ライセンシング
  • 市場の定義とレポートの範囲

第3章 ジェネリック医薬品市場

  • 市場概要
  • 2015年の世界市場
  • 地域別動向
  • 売上予測
  • 地域別市場の予測
  • 主要市場の予測
  • 成長を牽引する市場
  • 市場シェアの変遷
  • 世界市場:促進因子と阻害因子

第4章 米国のジェネリック医薬品市場

第5章 欧州主要国のジェネリック医薬品市場

第6章 アジア太平洋地域のジェネリック医薬品市場

第7章 新興のジェネリック医薬品市場

  • 市場概要
  • ブラジル
  • ロシア
  • メキシコ
  • 韓国
  • トルコ

第8章 ジェネリック医薬品市場における大手企業

  • 継続的な拡大
  • Teva
  • Novartis
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi

第9章 ジェネリック医薬品市場の定性分析

第10章 専門家の意見

第11章 結論

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0109

What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market

  • US
  • EU5
  • Asia-Pacific
  • Emerging markets

See revenue forecasts for the leading international markets

How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:

  • US
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Brazil
  • Russia
  • Mexico
  • South Korea
  • Turkey

Leading companies and potential for market growth

Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.

Our work analyses the key companies in the market. See visiongain's analysis of ten leading companies, including:

  • Teva
  • Novartis (Sandoz)
  • Allergan
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Generic drugs revenue and share of total revenue
  • Historic revenue (where available), analysis and discussion of company performance
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the generic drugs industry?

Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future generic drug opportunities

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you

In summary, our 306-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Generic Drugs market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for major regional markets - US, EU5, Asia-Pacific, Emerging markets
  • Revenue forecasts to 2026 for fourteen leading national markets - US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey
  • Assessment of leading companies - analysis of products, revenue (where available), mergers & acquisitions, and pipelines
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Generic Drugs: Market Overview
  • 1.2. Global Generic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQs)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. An Introduction to Generic Drugs

  • 2.1. An Introduction to the Rise of Generic Drugs
  • 2.2. What Are Generic Drugs?
    • 2.2.1. Generic Active Ingredients
  • 2.3. A Brief Overview of the Pharmaceutical Industry
    • 2.3.1. Brief History of Generic Drugs
    • 2.3.2. The Hatch-Waxman Act: The Rise of Generics
  • 2.4. Demonstrating Bioequivalence: A Major Factor in Approving Generics
  • 2.5. Types of Generics - Authorised, Branded and Unbranded
  • 2.6. Complex Generics
  • 2.7. Classification of Generic Drugs Markets
  • 2.8. Is Generic Substitution Bad News for Big Pharma Business?
    • 2.8.1. The 'Evergreening' of Pharmaceutical Products
  • 2.9. Regulation of Generic Drugs
    • 2.9.1. Regulation in the US
    • 2.9.2. Regulation in Europe
    • 2.9.3. Regulation in Japan
    • 2.9.4. Regulation in China
  • 2.10. Compulsory Licensing
  • 2.11. Market Definition and Scope of This Report
    • 2.11.1. Market Sizing and Revenue Reporting
    • 2.11.2. Currency Exchange Rates in This Report

3. Generic Drugs Market 2016-2026

  • 3.1. The Global Generic Drugs Market: Market Overview
    • 3.1.1. Segmenting the Global Generic Drugs Market
  • 3.2. The Rise of the Global Generic Drugs Market in 2015
  • 3.3. Changes in the Regional Distribution of the Generic Drugs Market 2014-2015
  • 3.4. The Global Generic Drugs Market: Sales Forecast 2016-2026
  • 3.5. Generic Drugs: Regional Market Forecast: 2016-2026
    • 3.5.1. Changes in Generic Drug Regional Market Shares 2016-2026
  • 3.6. Leading National Markets for Generic Drugs: Market Forecast 2016-2026
  • 3.7. National Markets that will Drive Generic Drugs Growth
  • 3.8. Changes in Market Shares by National Market 2016-2026
  • 3.9. Drivers and Restraints for the Global Generic Drugs Market 2016-2026

4. US Generic Drugs Market, 2016-2026

  • 4.1. Generic Drugs in the US: Market Overview
    • 4.1.1. The Effects of Generics on Healthcare Spending in the US
    • 4.1.2. The Hatch-Waxman Act and Its Ongoing Effects
    • 4.1.3. Consolidation in the Drug Development and Supply Chain Driving US Generics
  • 4.2. US Historical Generic Penetration Rates
  • 4.3. Leading Companies Operating within the US Generic Drugs Market
    • 4.3.1. The Increasing Acceptance of Generics amongst Consumers
    • 4.3.2. Affordable Care Act: Expanding Medicare Coverage
  • 4.4. The US Generic Drugs Market: Drivers and Restraints 2016-2026
  • 4.5. The US Generic Drugs Market Forecast: 2016-2026
  • 4.6. The US Generic Drugs Market - Strategic Analysis
    • 4.6.1. Will Biosimilars Dictate the Future of the US Generics Market?
    • 4.6.2. The Backlog of ANDA Applications
    • 4.6.3. The Generic Drug User Fee Amendments (GDUFA)
    • 4.6.4. Shortages of Generic Drugs Will Restrain the Market
    • 4.6.5. The Anti-Competitive ‘Pay for Delay' Effect
  • 4.7. US Generic Drugs Market: A Range of Factors Contributing to Growth

5. Leading European Generic Drug Market, 2016-2026

  • 5.1. European Generic Drugs: Market Overview
    • 5.1.1. The EU5
    • 5.1.2. Why Growth in Some Markets is Being Hindered?
    • 5.1.3. Predominant Pricing Systems and Generic Penetration In European Markets
    • 5.1.4. Will Europe Move towards Free-Pricing Systems?
    • 5.1.5. Challenges in the European Regulatory Environment
    • 5.1.6. Ending Anti-Competitive ‘Pay for Delay' Tactics in Europe
    • 5.1.7. FDA and EMA Joint Data Sharing and Inspections
  • 5.2. EU5 Generic Drugs Market Forecast: 2016-2026
  • 5.3. EU5 Market Share Breakdown 2016-2026
  • 5.4. Germany: New Reforms to Medicinal Pricing May Impact Market Entry
    • 5.4.1. German Generic Drugs Market: Generic Penetration By Volume, 2000-2015
    • 5.4.2. German Generic Drugs Market: Generic Penetration by Value, 2000-2015
  • 5.5. UK Generic Drugs Market: A Mature Market with Growth Potentials
    • 5.5.1. UK Generic Drugs Market: Sales Forecast 2016-2026
    • 5.5.2. Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
    • 5.5.3. UK Generic Drugs Market: Generic Penetration by Volume, 2000-2015
    • 5.5.4. UK Generic Drugs Market: Generic Penetration by Value, 2000-2015
    • 5.5.5. Pharmacists as Enforcers of Generic Substitution
    • 5.5.6. Pay Time for ‘Pay-For-Delay'
    • 5.5.7. GSK: Widening the Gate to Accessible Medicines
  • 5.6. French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
    • 5.6.1. French Generic Drugs Market: Sales Forecast 2016-2026
    • 5.6.2. French Generic Drugs Market: Generic Penetration by Volume, 2000-2015
    • 5.6.3. French Generic Drugs Market: Generic Penetration by Value, 2000-2015
  • 5.7. Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
    • 5.7.1. The Tightening of Italy's Patent Legislations
    • 5.7.2. The Italian Healthcare System - A Tale of Falling Budgets
    • 5.7.3. Italian Generic Drugs Market: Sales Forecast: 2016-2026
    • 5.7.4. Italian Generic Drugs market: Generic Penetration by Volume
    • 5.7.5. Italian Generic Drugs Market: Generic Penetration by Value
  • 5.8. Spain
    • 5.8.1. Cost-Containment Measures Helping to Boost Generic Drug Use
    • 5.8.2. Spanish Generic Drugs Market: Sales Forecast 2016-2026
    • 5.8.3. Spanish Generic Drugs Market: Generic Penetration by Volume, 2000-2015
    • 5.8.4. Spanish Generic Drugs Market: Generic Penetration by Value, 2000-2015

6. Asia-Pacific Generic Drugs Market, 2016-2026

  • 6.1. Generic Drugs in the Asia-Pacific Market: Market Overview
  • 6.2. Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
    • 6.2.1. The Major Drivers of Growth in the Chinese Generics Market
    • 6.2.2. Chinese Generic Drugs Market: Sales Forecast 2016-2026
    • 6.2.3. Compulsory Licensing of Generic Drugs
    • 6.2.4. Expansion of Healthcare Coverage and Reimbursement
    • 6.2.5. Chinese Generic Drugs Market: Generic Penetration by Volume, 2000-2015
    • 6.2.6. Chinese Generic Drugs Market: Generic Penetration by Value, 2000-2015
    • 6.2.7. The Impacts of Price Controls and the Anhui Model
  • 6.3. Japanese Generic Drugs Market: High Barriers to Entry
    • 6.3.1. Public Perception of Generics in Japan
    • 6.3.2. Japanese Generic Drugs Market: Leading Companies
    • 6.3.3. Japanese Generic Drugs Market: Sales Forecast 2016-2026
    • 6.3.4. Japanese Generic Drugs Market: Generic Penetration by Volume, 2000-2015
    • 6.3.5. Japanese Generic Drugs Market: Generic Penetration by Value, 2000-2015
    • 6.3.6. Government Initiatives Driving Generic Penetration
    • 6.3.7. Japanese Attitudes to Generic Drugs
  • 6.4. Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
    • 6.4.1. Leading Companies in the Indian Generic Drugs Market
    • 6.4.2. Indian Generic Drugs Market: Sales Forecast 2016-2026
    • 6.4.3. The Reforms to India's Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
    • 6.4.4. Expansion of the National Healthcare Coverage Increases the Need for Generics
    • 6.4.5. Has Recent Manufacturing Quality Failures Dented India's Generics Growth?

7. Emerging Generic Drugs Market, 2016-2026

  • 7.1. Generic Drugs in the Emerging Market: Market Overview
    • 7.1.1. Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
  • 7.2. Brazil
    • 7.2.1. Brazilian Generic Drugs Market: Sales Forecast 2016-2026
    • 7.2.2. Generics to Facilitate Low-Income Earner's Access to Medicines
    • 7.2.3. Foreign Generic Drug Manufacturers Entering the Brazilian Market
  • 7.3. Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
    • 7.3.1. Historical Trends in Russia's Pharmaceutical Production and Distribution
    • 7.3.2. The Pharma2020 Strategy - Healthcare and Industry Reform
    • 7.3.3. Self-Medication in Russia and the Integral Role of Pharmacies
    • 7.3.4. Russian Generic Drugs Market: Sales Forecast 2016-2026
  • 7.4. Mexico
    • 7.4.1. Government Programmes to Vitalise Generic Penetration in Mexico
    • 7.4.2. Regulatory Changes and the Inception of COFEPRIS
    • 7.4.3. Mexican Generic Drugs Market: Sales Forecast 2016-2026
  • 7.5. South Korea
    • 7.5.1. Pharmaceutical Price Controls and Measures Being Implemented in South Korea
    • 7.5.2. South Korean Generic Drugs Market: Sales Forecast 2016-2026
  • 7.6. Turkey
    • 7.6.1. Cost Cutting Measures and their Effects on Turkish Generics
    • 7.6.2. Will Turkey Become a Production Base for High Technology Products?
    • 7.6.3. Turkish Generic Drugs Market: Sales Forecast 2016-2026
    • 7.6.4. Regulatory Guidelines for Generic Drugs in Turkey
    • 7.6.5. How Effective has Turkey's Health Transformation Programme Been?

8. Leading Companies in the Generic Drugs market, 2016-2026

  • 8.1. Generic Drugs: Continuous Expansion to Rival
    • 8.1.1. The Leading Companies in the Global Generics Market
  • 8.2. Teva
    • 8.2.1. Teva: Historical Financial and Performance Analysis, 2010-2014
    • 8.2.2. Teva Generic Drugs Sales Forecast 2016-2026
    • 8.2.3. Teva and Allergan Spin-Off Generic Drug Deal
    • 8.2.4. Allergan: Historical Financial and Performance Analysis, 2010-2014
    • 8.2.5. Allergan: Developments in Generic Drug Segment Prior Mega-Deal
    • 8.2.6. Teva: Generic Drugs Portfolio Analysis, 2016
    • 8.2.7. Teva: What Future Moves Could We Expect?
  • 8.3. Novartis
    • 8.3.1. Novartis: Historical Financial and Performance Analysis, 2010-2014
    • 8.3.2. Novartis Generic Drugs Sales Forecast 2016-2026
    • 8.3.3. Novartis Generic Drugs Portfolio Analysis, 2016
    • 8.3.4. What Does the Future Hold for Novartis' Generic Drugs Business?
  • 8.4. Mylan
    • 8.4.1. Mylan: Historical Financial and Performance Analysis, 2010-2014
    • 8.4.2. Mylan Generic Drugs Sales Forecast 2016-2026
    • 8.4.3. Mylan: Recent Developments
    • 8.4.4. Mylan's Collaborative Efforts
    • 8.4.5. What Does the Future Hold for Mylan's Generic Drugs Business?
  • 8.5. Pfizer
    • 8.5.1. Pfizer: Historical Financial and Performance Analysis, 2010-2014
    • 8.5.2. Pfizer's Restructuring Strategy
    • 8.5.3. Pfizer's Done Deal with Hospira
    • 8.5.4. Pfizer Generic Drugs Sales Forecast 2016-2026
    • 8.5.5. Hospira: A Brief Overview of Operations
    • 8.5.6. Hospira: Historical Financial and Performance Analysis 2010-2014
    • 8.5.7. Hospira: Recent Developments
    • 8.5.8. Future Prospects for Pfizer's Generic Business
  • 8.6. Abbott
    • 8.6.1. Abbott: Historical Financial and Performance Analysis, 2010-2014
    • 8.6.2. Abbott Generic Drugs Sales Forecast 2016-2026
    • 8.6.3. Abbott: Recent Developments
    • 8.6.4. What Does the Future Hold for Abbott's Generic Drugs Business?
  • 8.7. Sun Pharma
    • 8.7.1. Sun Pharma's Business Areas
    • 8.7.2. Sun Pharma: Historical Financial and Performance Analysis, 2010-2014
    • 8.7.3. Sun Pharma Generic Drugs Sales Forecast 2016-2026
    • 8.7.4. Sun Pharma-Ranbaxy Acquisition
  • 8.8. Aspen
    • 8.8.1. Aspen: Historical Financial and Performance Analysis, 2010-2014
    • 8.8.2. Aspen Generic Sales Forecast 2016-2026
    • 8.8.3. Aspen: Recent Developments
    • 8.8.4. Future Outlook for Aspen's Generic Business
  • 8.9. Fresenius Kabi
    • 8.9.1. Fresenius Kabi: Historical Financial and Performance Analysis, 2010-2014
    • 8.9.2. Fresenius Kabi Generic Drugs Sales Forecast 2016-2026
    • 8.9.3. InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
    • 8.9.4. Fresenius Kabi's Joint Venture with PT Soho Global Health
    • 8.9.5. Future Prospects for Fresenius Kabi's Generics Business
  • 8.10. Sanofi
    • 8.10.1. Sanofi: Historical Financial and Performance Analysis, 2010-2014
    • 8.10.2. Sanofi Generic Sales Forecast 2016-2026
    • 8.10.3. Sanofi's Response to Lantus Competition
    • 8.10.4. Sanofi's Strategies to Develop Generic Sales
    • 8.10.5. Future Prospects for Sanofi's Generics Business

9. Qualitative Analysis of the Generic Drugs Market, 2016-2026

  • 9.1. Market Factors Influencing the Global Generic Drugs Market
  • 9.2. SWOT Analysis of the Global Generic Drugs Market, 2016-2026
    • 9.2.1. Strengths
    • 9.2.2. Weaknesses
    • 9.2.3. Opportunities
    • 9.2.4. Threats
  • 9.3. Porter's Five Force Analysis of the Global Generic Drugs Market, 2016-2026
    • 9.3.1. Power of Buyers: Medium
    • 9.3.2. Power of Suppliers: Low
    • 9.3.3. Rivalry among Competitors: High
    • 9.3.4. Threat of New Entrants: High
    • 9.3.5. Threat of Substitutes: Low

10. Conclusions

  • 10.1. Overview of Current Market Conditions and Market Forecast, 2016-2026
  • 10.2. Generic Drugs as a Strategic Tool in Healthcare
  • 10.3. Major Drivers of Growth for Generic Drugs, 2016-2026
  • 10.4. The Regulatory Landscape for Generic Drugs
  • 10.5. Leading Generic Drug Manufacturers
  • 10.6. Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2016-2026
  • 10.7. Generic Penetration by Volume in Leading National Markets
  • 10.8. What Does The Future Hold For The Global Generic Drugs Market?

11. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1: Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2014-2026 (Redacted Data)
  • Table 2.1: Types Of Drug Names, 2016
  • Table 2.2: Currency Exchange Rates, 2015
  • Table 3.1: The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2014 and 2015
  • Table 3.2: The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2014 and 2015
  • Table 3.3: The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.4: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2026
  • Table 3.5: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014, 2020, and 2026
  • Table 3.6: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
  • Table 3.6: (cont'd) The Global Generic Drugs Market Forecast:: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2014-2026
  • Table 3.7: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020, 2020-2026, 2014-2026
  • Table 3.8: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014, 2020, and 2026
  • Table 3.9: lobal Generic Drugs Market Drivers and Restraints, 2014-2026
  • Table 4.1: US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
  • Table 4.2: US Generic Drugs Market Drivers and Restraints, 2016-2026
  • Table 4.3: US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.1: The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2014 and 2015
  • Table 5.2: EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.3: The EU5 Generic Drugs Market: Market Share (%) by Country, 2014, 2020, 2026
  • Table 5.4: The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.5: German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 5.6: German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 5.7: The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.8: UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 5.9: UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 5.10: The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.11: French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 5.12: French Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 5.13: The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.14: Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 5.15: Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 5.16: The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2014-2026
  • Table 5.17: Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 5.18: Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 6.1: The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 6.3: Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 6.4: The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 6.5: Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Table 6.6: Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Table 6.7: The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 6.8: Leading Drug Types In Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 & 2026
  • Table 7.1: The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.2: The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.3: The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.4: The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 7.5: The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.1: Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2014
  • Table 8.2: Teva: Company Overview, 2014-2015
  • Table 8.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2009-2013
  • Table 8.4: Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.5: Allergan: Company Overview 2014-2015
  • Table 8.6: Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.7: Novartis: Overview, 2014-2015
  • Table 8.8: Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.9: Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.10: Mylan: Company Overview, 2014-2015
  • Table 8.11: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.12: Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.13: Pfizer: Company Overview, 2014-2015
  • Table 8.14: Pfizer: Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.15: Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.16: Hospira: Company Overview, 2013-2014
  • Table 8.17: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
  • Table 8.18: Allergan: Company Overview, 2014-2015
  • Table 8.19: Abbott: Company Overview, 2014-2015
  • Table 8.20: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.21: Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.22: Sun Pharmaceuticals: Company Overview, 2014-2015
  • Table 8.23: Sun Pharma: Historical Generic Drugs Sales (Rs.bn and $bn), 2010-2014
  • Table 8.24: Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.25: Aspen: Company Overview, 2014-2015
  • Table 8.26: Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2010-2014
  • Table 8.27: Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.28: Fresenius Kabi: Company Overview, 2014-2015
  • Table 8.29: Fresenius Kabi: Historical Generic Drugs Sales (€bn and $bn), 2010-2014
  • Table 8.30: Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 8.31: Sanofi: Company Overview, 2014-2015
  • Table 8.32: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Table 8.33: Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 9.1: SWOT Analysis of the Generic Drugs Market, 2016-2026
  • Table 9.2: World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2014-2026
  • Table 10.1: Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2014, 2020 and 2026
  • Table 10.2: Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2015
  • Table 10.3: Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2014, 2020 and 2026
  • Table 10.4: US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Table 10.5: BRIC Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Table 10.6: Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Table 10.7: Generic Drug Penetration by Volume in Leading National Markets (%), 2015

List of Figures

  • Figure 1.1: Global Generic Drugs Market Segmentation
  • Figure 2.1: EU Data Exclusivity for Generics: Possible Scenarios, 2016
  • Figure 3.1: The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2014
  • Figure 3.2: The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
  • Figure 3.3: The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2014
  • Figure 3.4: The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
  • Figure 3.5: Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2014-2026
  • Figure 3.6: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2014
  • Figure 3.7: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2020
  • Figure 3.8: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2026
  • Figure 3.9: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2020
  • Figure 3.10: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2020-2026
  • Figure 3.11: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2014-2026
  • Figure 3.12: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2014
  • Figure 3.13: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2020
  • Figure 3.14: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2026
  • Figure 4.1: US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2004-2015
  • Figure 4.2: US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
  • Figure 5.1: The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2014
  • Figure 5.2: The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
  • Figure 5.3: Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 5.4: The EU5 Generic Drugs Market: Market Share (%) by Country, 2014
  • Figure 5.5: The EU5 Generic Drugs Market: Market Share (%) by Country, 2020
  • Figure 5.6: The EU5 Generic Drugs Market: Market Share (%) by Country, 2026
  • Figure 5.7: The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.8: German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 5.9: German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Figure 5.10: The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.11: UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 5.12: UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Figure 5.13: The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.14: French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 5.15: French Generic Drugs Market: Generic Penetration by Value (%), 2000-2015
  • Figure 5.16: The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 5.17: Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 5.18: Italian Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Figure 5.19: The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2014-2026
  • Figure 5.20: Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 5.21: Spanish Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Figure 6.1: China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 6.2: The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 6.3: Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2000-2015
  • Figure 6.4: Chinese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2000-2015
  • Figure 6.5: The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
  • Figure 6.6: Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2000-2015
  • Figure 6.7: Japanese Generic Drugs Market: Generic Penetration by Value (%) and AGR (%) 2000-2015
  • Figure 6.8: The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
  • Figure 6.9: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2015
  • Figure 6.10: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2020
  • Figure 6.11: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2026
  • Figure 7.1: Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 7.2: The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
  • Figure 7.3: The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.4: The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 7.5: The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2014-2026
  • Figure 7.6: The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.1: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2014
  • Figure 8.2: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
  • Figure 8.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.4: Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.5: Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.6: Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.7: Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.8: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.9: Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.10: Pfizer: Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.11: Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.12: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.13: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.14: Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.15: Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2010-2014
  • Figure 8.16: Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.17: Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.18: Aspen: Historical Revenue ($bn) and AGR (%), 2010-2014
  • Figure 8.19: Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.20: Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2010-2014
  • Figure 8.21: Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.22: Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 8.23: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2010-2014
  • Figure 8.24: Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 9.1: World 65+ Population Forecast: Size (m) and AGR (%), 2014-2026
  • Figure 9.2: Porter's Five Force Analysis of the Global Generic Drugs Market, 2016
  • Figure 10.1: Global Generic Drugs Market Forecast: Revenue ($bn), 2014, 2020 and 2026
  • Figure 10.2: US, Japan and EU5 Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 10.3: BRIC Generic Drugs Market Forecast: ($bn), 2014-2026
  • Figure 10.4: Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2014-2026
  • Figure 10.5: Generic Drug Penetration by Volume in Leading National Markets (%), 2015

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • Alcon (Novartis)
  • Allergan (Actavis)
  • Amgen
  • Anda Inc
  • APP Pharmaceuticals
  • Arrow Group (Actavis)
  • Ascent Pharmahealth (Actavis)
  • ASKA Pharmaceuticals
  • Aspen
  • AstraZeneca
  • Bergamo (Amgen)
  • Bioniche Pharma (Mylan)
  • BMP Sunstone (Sanofi)
  • CFR Pharmaceuticals (Abbott)
  • Cipla
  • Dabur Pharma (Fresenius Kabi)
  • Daiichi Sankyo
  • Dalim BioTech
  • Dr Reddy's Laboratory
  • Ebewe Pharma (Novartis)
  • Eden Biopharm Group
  • Egis
  • Elder Pharmaceuticals (Torrent Pharmaceuticals)
  • Eli Lilly
  • Elyson Pharmaceuticals
  • EMS Sigma Pharma
  • Eurofarma Laboratories
  • Farmacias Similares
  • Fenwal (Fresenius Kabi)
  • Forest Laboratories (Actavis)
  • Foshan Chanbende Development
  • Fougera Pharmaceuticals (Novartis)
  • Fresenius Kabi
  • Fresenius SE & Co
  • Fuji Pharma
  • Gedeon Richter
  • Genfar S.A (Sanofi)
  • Genzyme (Sanofi)
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Greenstone (Pfizer)
  • Grupo Sanborns
  • Grupo Uriach
  • Hospira (Pfizer)
  • IDEV Technologies (Abbott)
  • Ilsung Pharmaceuticals
  • InnoPharma Inc
  • Itero Biopharmaceuticals
  • Janssen
  • Javelin Pharmaceuticals (Hospira)
  • Kmart
  • KMS Pharmaceutical
  • Kowa Pharmaceuticals
  • Krka
  • Labesfal Genéricos (Fresenius Kabi)
  • Laboratorio Sanderson (Fresenius Kabi)
  • Laboratorios Best
  • Laboratorios Kendrick (Sanofi)
  • Lek (Novartis)
  • Lupin
  • Mayne Pharma (Hospira)
  • Medley (Sanofi)
  • Merck KGaA
  • MN Pharma (Amgen)
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nexus Pharmaceuticals
  • Nichi-Iko
  • Nippon Chemiphar
  • Novartis (Sandoz)
  • Novo Nordisk
  • OptiMedica (Abbott)
  • Orchid Chemicals & Pharmaceuticals
  • Oriel Therapeutics (Novartis)
  • Parenteral Drugs India Ltd
  • Perrigo
  • Pfizer
  • Piramal (Abbott Laboratories)
  • Pliva (Teva)
  • PT Soho Global Health
  • Ranbaxy (Sun Pharmaceuticals)
  • Rimsa
  • Roche
  • Sabex (Novartis)
  • Sanofi
  • Sawai Pharmaceuticals
  • Schein Pharmaceutical (Actavis)
  • Shelys (Aspen)
  • Sigma Pharmaceuticals (Aspen)
  • Solvay Pharmaceuticals (Abbott)
  • Specifar Pharmaceuticals (Actavis)
  • STADA Arzneimittel
  • Sun Pharma
  • Synthon
  • Takeda
  • Taiyo Pharmaceuticals
  • Teuto Brasileiro (Pfizer)
  • Teva
  • The Laboratory Of Analytical Services International Ltd
  • Towa
  • UDL Laboratories
  • Uteron Pharma (Actavis)
  • Valeant Pharmaceuticals
  • Wal-Mart
  • Warner Chilcott (Actavis)
  • Wockhardt
  • Wyeth (Pfizer)
  • Zentiva (Sanofi)
  • Zhejiang Chiral Medicine Chemicals Co. Ltd
  • Zhejiang Hisun Pharmaceutical
  • Zydus Cadila

Organisations Mentioned in the Report

  • Assogenerici [Italy]
  • Blue Cross Blue Shield Association (BCBSA) [US]
  • British Generic Manufacturers Association (BGMA)
  • Caisse Nationale de l'Assurance Maladie (CNAM) [France]
  • Center for Drug Evaluation and Research (CDER) [US]
  • Centers for Medicare and Medicaid Services [US]
  • China Food and Drug Administration (CFDA)
  • COFEPRIS [Mexico]
  • Competion and Markets Authority (CMA) [UK]
  • Congressional Budget Office (CBO) [US]
  • European Commission
  • European Generics Medicines Association (EGA)
  • European Medicines Agency (EMA)
  • European Patent Office (EPO)
  • Federal Trade Commission (FTC) [US]
  • Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
  • Food and Drugs Administration (FDA) [US]
  • Gesund-heits-bericht-erstat-tung des Bundes (Federal Health Monitoring System, Germany)
  • General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
  • General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
  • Medicine and Healthcare products Regulatory Agency (MHRA)
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Ministry of Human Resources and Social Security (MOHRSS)
  • National Development and Reform Commission (NDRC)
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority [India]
  • Pan American Health Organization (PAHO)
  • Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
  • Queen Mary University of London
  • Servicio Sanitario Nazionale (SSN) [Italy]
  • United Nations' Department of Economic and Social Affairs
  • US Generic Pharmaceutical Association (GPhA)
  • Veropharm (Abbott)
  • World Health Organization (WHO)
  • World Trade Organisation (WTO)
Back to Top